The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 204,831 |
| Gain from sale of priority review voucher | 0 |
| Deferred tax asset | 22,845 |
| Depreciation | 5,724 |
| Accretion of marketable securities | -498 |
| Amortization of operating lease right-of-use assets | 827 |
| Stock-based compensation expense, net | 54,514 |
| Realized gain on investments | 5,953 |
| Other, net | 684 |
| Accounts receivable, net | 22,124 |
| Inventory | 6,286 |
| Prepaid taxes | 12,389 |
| Prepaid expenses and other assets | 2,270 |
| Lease liability | -578 |
| Other long-term liabilities | 2,280 |
| Accounts payable | 826 |
| Accrued rebates | 21,268 |
| Accrued expenses and other current liabilities | 14,104 |
| Accrued legal settlement | -31,250 |
| Net cash provided by (used in) operating activities | 200,865 |
| Proceeds from disposal of assets | 435 |
| Proceeds from sale of priority review voucher | 0 |
| Purchases of property and equipment | 11,951 |
| Purchases of investments | 422,540 |
| Maturities of investments | 375,639 |
| Net cash (used in) provided by investing activities | -58,417 |
| Proceeds from issuance of common stock, net | 0 |
| Proceeds from exercise of stock options | 22,661 |
| Taxes paid for employee tax withholding related to restricted stock units and taxes paid related to settlement of restricted stock awards-Restricted Stock Units RSU | 12,144 |
| Taxes paid for employee tax withholding related to restricted stock units and taxes paid related to settlement of restricted stock awards-Restricted Stock | 1,812 |
| Net cash provided by financing activities | 8,705 |
| Effect of exchange rate changes on cash and cash equivalents | 286 |
| Net change in cash and cash equivalents | 151,439 |
| Cash and cash equivalents at beginning of period | 344,865 |
| Cash and cash equivalents at end of period | 496,304 |
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)